Analyst Ratings January 22, 2026

Stephens Adjusts Calavo Growers Price Target Amid Mixed Q4 Performance and Upcoming Acquisition

New analysis reflects challenges in Fresh segment offset by gains in Prepared foods ahead of Mission Produce takeover

By Avery Klein CVGW
Stephens Adjusts Calavo Growers Price Target Amid Mixed Q4 Performance and Upcoming Acquisition
CVGW

Stephens has revised down its price target for Calavo Growers to $27.00 from $28.00, maintaining an Equal Weight rating. This adjustment follows Calavo's fourth-quarter performance, where underperformance in its Fresh business weighed on results despite strength in Prepared foods. Meanwhile, the planned acquisition by Mission Produce is seen as a strategic fit that could stabilize future earnings.

Key Points

  • Stephens reduced Calavo Growers' price target to $27.00, maintaining an Equal Weight rating, with the target close to current market prices.
  • Calavo’s fourth-quarter performance saw weakness in Fresh segment pricing and volume, partially offset by Prepared segment strength, leading to adjusted EPS and revenue misses.
  • Mission Produce’s planned acquisition of Calavo is considered strategically complementary and is expected to stabilize earnings through integration synergies post regulatory approvals.

Stephens has lowered its price target for Calavo Growers (NASDAQ:CVGW) to $27.00 from the previous $28.00, while keeping its Equal Weight rating intact. The revised target closely matches the current trading price of $27.04, though data from InvestingPro indicates that Calavo Growers may still be undervalued relative to its fair value estimate.

This downward adjustment follows Calavo's fourth-quarter 2025 results, which slightly missed analyst expectations. The key driver behind the softer performance was the Fresh segment, which faced reduced pricing and volume pressures. Conversely, Calavo's Prepared segment delivered robust results that partially offset the softness. Despite these mixed outcomes, the company sustained profitability with diluted earnings per share (EPS) of $1.11 over the trailing twelve months, although its gross profit margin was modest at 9.82%.

Stephens highlighted that Calavo's management is making "tangible progress" in enhancing the Prepared division. However, the Fresh business continues to face challenges stemming from commodity price fluctuations and near-term operational obstacles. These vulnerabilities have constrained the segment's margin and revenue performance.

Overshadowing the quarterly financials was the announcement of Mission Produce's agreement to acquire Calavo Growers. Stephens described this move as a logical strategic alignment, stemming from complementary sourcing, distribution, and value-added capabilities across both companies. Pending standard regulatory approvals, the acquisition is expected to help Calavo stabilize its earnings profile through realized integration synergies.

Additional details from Calavo's Q4 earnings reveal adjusted EPS of $0.25, falling short of the $0.38 estimate. Quarterly revenue totaled $124.7 million, significantly below consensus forecasts of $153.7 million and declining from $170 million in the same quarter last year. The company attributed this revenue decline primarily to lower avocado prices and reduced volumes in the Fresh segment.

The upcoming merger with Mission Produce represents a pivotal development for Calavo Growers, with implications for the company's operational strategy going forward. Investors remain attentive to how the integration will unfold amid this challenging market backdrop.

Risks

  • Ongoing volatility in commodity prices impacting Calavo's Fresh segment profitability and volume growth.
  • Execution risks in managing near-term challenges within the Fresh business could continue to pressure margins.
  • Uncertainties related to the integration process and regulatory approval of the Mission Produce acquisition, which may affect expected earnings stabilization.

More from Analyst Ratings

BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026 BWS Financial Boosts A10 Networks Price Target Citing AI-Driven Network Traffic Feb 20, 2026 Supreme Court Ruling Boosts Steve Madden Outlook, Analysts Say Feb 20, 2026 UBS Lowers Carvana Price Target Citing Higher Costs, Keeps Buy Rating Feb 20, 2026